AF burden 2023

RATIONALE & BACKGROUND

Atrial fibrillation (AF) is a major risk factor for stroke. Despite substantial advances in both the treatment for AF and the prevention of AF related strokes, fundamental questions on pathophysiological mechanisms, risk assessment, prevention and therapy are still unresolved. There is an unmet medical need for clinically applicable concepts in AF diagnostic workup and individual patient risk evaluation.

AIMS OF THE CONFERENCE

Primary Aims: 

  • Developing a consensus statement that defines the concept of AF burden as a clinically applicable principle to inform clinical evaluation in regard to diagnostic value, risk assessment and therapeutic options.

Secondary Aims: 

  • Addressing key questions that help to define the scope of AF burden,
  • Developing a platform and structure for interdisciplinary expert discussion and consensus process for subsequent topics.

MEETING STRUCTURE AND CONCEPT OUTLINE

Scientific program nucleus

Co-Chairs
John Camm
John Camm
(UK) down-arrow
Wolfram Doehner
Wolfram Doehner
(GE) down-arrow
Nucleus
Giuseppe Boriani
Giuseppe Boriani
(IT) down-arrow
Karl Georg Haeusler
Karl Georg Haeusler
(GE) down-arrow
Tatjana Potpara
Tatjana Potpara
(SER) down-arrow

FACULTY

19 internationally renowned experts in AF and stroke prevention with high clinical and academic standing. A full time in-person attendance is required to ensure recognition of consensus voting (no late arrival or early departure).

Greg Lip

Gregory Lip

Jose Merino

Jose Merino

Jesper Svendsen

Jesper Svendsen

Emma Svennberg

Emma Svennberg

Rolf Wachter

Rolf Wachter

Carina Blomstrom Lundqvist

Carina Blomstrom Lundqvist

Isabelle van Gelder

Isabelle van Gelder

Renate Schnabel

Renate Schnabel

George Ntaios

George Ntaios

Karapanayiotides

Theodore Karapanayiotides

Dobromir Dobrev

Dobromir Dobrev

Daniel Singer

Daniel Singer

Rod Passman

Rod Passmann

Jeff Healey

Jeff Healey

Luciano Sposato (WSO)

Luciano Sposato (WSO)

Taya Glotzer

Taya Glotzer

Ben Freedman

Ben Freedman

Packer Douglas

Douglas L Packer

Observer

Industry partners with an interest in the topic will be invited: 

  • to observe the academic exchange
  • to contribute to the debate in selected aspects

Program Logistics

Two half days (afternoon – morning) with 2-3 sessions per half day, each addressing a specified topic (key question) in a defined structure:

  • A kickstart presentation to introduce the topic and the unmet need (8 min max, invited presenter)
  • Open discussion round the table (all)
  • Presentation of the key question and options for a consensus (session chair)
  • Discussion of the consensus options (all)
  • Voting on a consensus for each question (all)

The final session will address the consensus statement on a clinical definition of AF burden.

  • Impulse presentation to summarise the unmet need and the discussed key questions
  • Propose a clinical definition of AF burden (session chair)
  • Discussion and Voting for a consensus (all)

ORGANIZATION

Translational Medicine Academy (TMA)

Picasso Platz 8,
4052 Basel
Switzerland

CONTACTS

CHARLES SCHOEN – Operations Director

T. +33 (0) 608 18 77 08
Email : charles.schoen@tmacademy.org

FAB POLLER – Industry Relations

T. +33 (0) 699 66 19 73
Email : fpoller@tmacademy.org